****

Irvine Auditorium

3401 Spruce Street, Philadelphia, PA 19104

**Overview**

Penn Medicine and Children's Hospital of Philadelphia remain at the forefront of cell and gene therapy, solidifying Philadelphia's status as "Cellicon Valley." The University of Pennsylvania continues to lead in CAR-T cell research, reflecting its ongoing commitment to innovation in this field, particularly through the pioneering work of the **Center for Cellular Immunotherapies**.

While CAR T-cell therapy has already revolutionized cancer treatment, the field continues to evolve rapidly. This activity provides a **unique opportunity to interact with world-renowned experts in CAR T-cell therapy for cancer, hematologic disorders and autoimmune diseases**.

**Clinicians** will discover cutting-edge strategies to optimize patient care and overcome challenges in the field. **Researchers** will delve into the scientific and technical breakthroughs shaping the future of this revolutionary treatment. **Business leaders** will gain a comprehensive understanding of the CAR T-cell therapy landscape with a focus on commercial partnering, product development and entrepreneurship.

**Who Should Attend**

These activities are intended for both adult and pediatric hematologist-oncologists, medical oncologists, hematologists, hematopathologists, immunologists, immunobiologists, transfusion medicine, researchers, pharmacists, fellows, nurses, nurse practitioners, physician assistants, industry professionals and other healthcare professionals interested in the latest advances in cell and gene therapy. Additionally, patients and their caregivers, family members, advocates and members of the public who may benefit from understanding current innovative approaches to gene and cell therapy are also invited.

**Learning Objectives**

Upon completion of this symposium, participants should be able to:

* Evaluate barriers to equitable CAR-T cell therapy access and evaluate how philanthropic initiatives can improve access.
* Summarize recent advances in CAR T-cell therapy, including applications for autoimmunity and immunoregulation.
* Discuss the challenges and future directions of translating stem cell research into clinical practice.
* Evaluate the therapeutic potential of stem cell-based interventions.
* Explain how gene editing technologies are used in stem cell engineering.
* Review how mRNA technology is transforming cell and gene therapies.
* Identify novel targets and strategies for overcoming treatment resistance in solid tumors.
* Analyze the risks and benefits of cell and gene therapies, including clinical and long-term outcomes.
* Explore the career paths and influence of successful women leaders in STEM.
* Assess the cost-effectiveness of cell and gene therapies within the context of healthcare economics.
* Examine strategies for successful technology transfer and collaboration between academia and industry.
* Define the role of industry partnerships and regulatory pathways in advanced therapy development.
* Recognize effective leadership strategies in the cell and gene therapy field.
* Analyze the challenges and opportunities in commercializing cell and gene therapies.
* Outline the process of translating advanced therapies from research to clinical practice and commercialization.

**AGENDA**

**Wednesday, April 30, 2025**

 **4:00 pm In-Person: Check-In and Visit Exhibits**

 **5:00 pm WELCOME REMARKS**

[Jonathan Epstein, MD](https://www.med.upenn.edu/evpdean/epstein.html) | University of Pennsylvania

 **5:05 pm SPECIAL ADDRESS**

**CAR T-Cell Therapy in 2025: Navigating Innovations and Overcoming Challenges**

[Carl H. June, MD](http://pathology.med.upenn.edu/department/people/447/carl-h-june%20or%20https%3A/www.med.upenn.edu/cci/junelab/) | Penn Medicine | Symposium Co-Chair

 **5:35 pm Discussion**

Moderator: [Bruce L. Levine, PhD](http://pathology.med.upenn.edu/department/people/291/bruce-l-levine) | Penn Medicine | Symposium Co-Chair

 **5:45 pm SPECIAL GUEST SPEAKER**

**Developing mRNA for Therapy**

[Katalin Karikó, PhD](https://www.pennmedicine.org/providers/profile/katalin-kariko) | Penn Medicine

 **6:15 pm Discussion**

Moderator: [Bruce L. Levine, PhD](http://pathology.med.upenn.edu/department/people/291/bruce-l-levine) | Penn Medicine | Symposium Co-Chair

 **6:30 pm NETWORKING RECEPTION AND BOOK SIGNING**

 **7:30 pm Adjourn**

**Thursday, May 1, 2025**

 **7:00 am In-Person: Check-In, Visit Exhibits and Breakfast**

 **8:00 am Welcome Remarks­**

[Carl H. June, MD](http://pathology.med.upenn.edu/department/people/447/carl-h-june%20or%20https%3A/www.med.upenn.edu/cci/junelab/) | Penn Medicine | Symposium Co-Chair

[Larry Jameson, MD, PhD](https://president.upenn.edu/meet-president)  | Interim President of the University of Pennsylvania

**8:15 am KEYNOTE PANEL: Closing the Gap: Philanthropy's Role in Equitable CAR-T Access**

Moderators: [Carl H. June, MD](http://pathology.med.upenn.edu/department/people/447/carl-h-june%20or%20https%3A/www.med.upenn.edu/cci/junelab/) | Penn Medicine | Symposium Co-Chair

[David L. Porter, MD](https://www.pennmedicine.org/providers/profile/david-porter) | Penn Medicine | Symposium Co-Chair

Panel:

[Valerie A. Arkoosh, MD, MPH](https://www.pa.gov/en/agencies/dhs/departments-offices/dhs-executive-leadership.html) |  Pennsylvania Secretary of Human Services

[Lee Greenberger, PhD](https://www.lls.org/person/lee-greenberger-phd) | Leukemia Lymphoma Society

[Tom Whitehead](https://www.linkedin.com/in/tom-whitehead-08ba32102) | Emily Whitehead Foundation

**PLENARY SESSION 1: Risk and Cost vs Reward and Benefit for Cell and Gene Therapies**

Moderator: [Stephan A. Grupp, MD, PhD](https://www.chop.edu/doctors/grupp-stephan-a) | Children’s Hospital of Philadelphia| Symposium Co-Chair

 **9:00 am TBA**

[Bruce L. Levine, PhD](http://pathology.med.upenn.edu/department/people/291/bruce-l-levine) | Penn Medicine | Symposium Co-Chair

 **9:20 am TBA**

**Speaker TBD**

 **9:40 am TBA**

[Stephen J. Schuster, MD](https://www.pennmedicine.org/providers/profile/stephen-schuster) | Penn Medicine

**10:00 am Discussion**

**10:10 am Oral Presentation Winner**

**PLENARY SESSION 2:** **Leadership in Cell and Gene Therapies: The XX Factor**

Moderator: [Amanda Finck, BS](https://www.linkedin.com/in/amandafinck) | Penn Medicine

**10:15 am** **Leading the Charge For In Vivo Cell Therapy for The Treatment of Autoimmune Disorders**

[Laura Shawver, PhD](https://relaytx.com/our-team/laura-shawver-ph-d/) | Capstan Therapeutics

**10:30 am TBA**

[Elizabeth M. Jaffee, MD, FAACR, FACP](https://publichealth.jhu.edu/academics/phd-dept-of-biochemistry-and-molecular-biology/about-the-bmb-phd/meet-our-faculty/elizabeth-jaffee) | Johns Hopkins

**10:45 am CAR-T Trailblazers: Grand Adventures and the Power of Women Leadership in Cell and Gene Therapy**

[Kristen M. Hege, MD](https://www.mersana.com/kristen-m-hege-m-d/) | Independent Board Member, Mersana, Adaptimmune, Kelonia

**11:00 am Discussion**

**11:25 am CONCURRENT SESSIONS I TBA**

**12:30 pm LUNCH BREAK | VISIT EXHIBITS**

**1:30 pm CONCURRENT SESSIONS II TBA**

**2:45 pm CONCURRENT SESSIONS III TBA**

**3:45 pm BREAK | VISIT EXHIBITS**

**PLENARY SESSION 3: Are In Vivo Cell Therapies the Key to the Future of Medicine?**

Moderator: [Bruce L. Levine, PhD](http://pathology.med.upenn.edu/department/people/291/bruce-l-levine) | Penn Medicine | Symposium Co-Chair

**4:00 pm Nucleoside-Modified mRNA-LNP Therapeutics**

[Drew Weissman, MD, PhD](https://www.pennmedicine.org/providers/profile/drew-weissman)  |  Penn Medicine

**4:20 pm TBA**

[Philip Johnson, MD](https://www.linkedin.com/in/philip-r-johnson-md/) | CEO, Interius

**4:40 pm In Vivo CAR T Therapeutics for Treatment of B Cell Lineage Malignancies**

[Andy Scharenberg, MD](https://www.linkedin.com/in/andy-scharenberg-2222b4a/) | CEO Umoja

**5:00 pm Discussion**

**5:10 pm Adjourn**

**Friday, May 2, 2025**

**7:00 am In-Person: Check-In, Visit Exhibits and Breakfast**

**8:00 am WELCOME**

[Carl H. June, MD](http://pathology.med.upenn.edu/department/people/447/carl-h-june%20or%20https%3A/www.med.upenn.edu/cci/junelab/) | Penn Medicine | Symposium Co-Chair

[Alison W. Loren, MD, MSCE](https://www.pennmedicine.org/providers/profile/alison-loren?fadf=pennmedicine&_ga=2.42368677.1250753100.1666798545-386578529.1639084756) | Penn Medicine

[Joseph W. St. Geme, III, MD](https://www.chop.edu/doctors/st-geme-joseph-w) | Children's Hospital of Philadelphia

**PLENARY SESSION 1: The Next Frontier in CAR T Autoimmune Disease**

Moderator: [David L. Porter, MD](https://www.pennmedicine.org/providers/profile/david-porter) | Penn Medicine | Symposium Co-Chair

**8:15 am Rationale for B Cell Directed Cell Therapy in Autoimmune Disease**

[Peter A. Merkel, MD, MPH](https://www.pennmedicine.org/providers/profile/peter-merkel) | Penn Medicine

 **8:35 am CD19 CAR T Cell Therapy in Autoimmune Disease**

[Georg Schett, MD](https://www.fau.eu/fau/organisation-and-committees/executive-board/prof-dr-georg-schett/) | University Hospital Erlangen

**8:55 am Novel Approaches to Cell Therapy in AI Disease**

[Carl H. June, MD](http://pathology.med.upenn.edu/department/people/447/carl-h-june%20or%20https%3A/www.med.upenn.edu/cci/junelab/) | Penn Medicine | Symposium Co-Chair

**9:15 am Discussion**

**PLENARY SESSION 2: Pioneering Novel Frontiers in Stem Cell Transplantation and Engineering**

Moderator: [Alexis A. Thompson, MD, MPH](https://www.chop.edu/doctors/thompson-alexis-a) | Children's Hospital of Philadelphia | Symposium Co-Chair

 **9:25 am TBA**

[Alice Bertaina, MD, PhD](https://med.stanford.edu/profiles/alice-bertaina) | Stanford University

 **9:45 am TBA**

[Stefano Rivella, PhD](https://www.chop.edu/doctors/rivella-stefano)  | Children's Hospital of Philadelphia

**10:05 am TBA**

[Saar I. Gill, MD, PhD](https://www.pennmedicine.org/providers/profile/saar-gill) | Penn Medicine

**10:25 am Discussion**

**10:35 am BREAK | VISIT EXHIBITS**

**PLENARY SESSION 3: Location, Location, Location: CAR T in Solid Tumors**

Moderator: [Carl H. June, MD](http://pathology.med.upenn.edu/department/people/447/carl-h-june%20or%20https%3A/www.med.upenn.edu/cci/junelab/) | Penn Medicine | Symposium Co-Chair

**10:55 am Latest on CAR/TCR NK for Liquid and Solid Tumors**

[Katy Rezvani, MD, PhD](https://faculty.mdanderson.org/profiles/katy_rezvani.html) | MD Anderson Cancer Center

**11:10 am Latest on GFRa4 CAR T**

[Donald L. Siegel, PhD, MD](https://pathology.med.upenn.edu/department/people/501/donald-l-siegel) | Penn Medicine

**11:25 am TBA**

[Joseph A. Fraietta, PhD](https://www.med.upenn.edu/apps/faculty/index.php/g5455356/p8575303) | Penn Medicine

**11:40 am Discussion**

**PLENARY SESSION 4: Celling Advanced Therapies: Navigating the Translation from Academia to Industry**

Moderator: [Katherine A. High, MD](https://www.med.upenn.edu/apps/faculty/index.php/g275/p12112https%3A/www.med.upenn.edu/apps/faculty/index.php/g275/p12112) | Penn Medicine

**11:50 am TBA**

[Beverly L. Davidson, PhD](https://www.chop.edu/clinical-staff/davidson-beverly-l) | CHOP

**12:10 pm TBA**

[Kiran Musunuru MD, PhD, MPH, ML, MRA](https://www.med.upenn.edu/cvi/musunuru-laboratory.html) | Penn Medicine

**12:30 pm TBA**

[Micheal Klichinsky PharmD, Phd](https://ir.carismatx.com/management/michael-klichinsky) | Carisma Therapeutics

**12:50 pm Discussion**

**1:00 pm CLOSING REMARKS**

 TBD (Cellicon Valley Co-Chair)

**1:05 pm ADJOURN**

 Lunch to Go

**11:20 am – 12:30 pm**

**CONCURRENT SESSIONS I**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **STEVE GRUPP / ALEXIS THOMAS****TRACK 1** **Pediatric Medical Care**Moderator: [Timothy S. Olson, MD, PhD](https://www.chop.edu/doctors/olson-timothy-s) Children's Hospital of Philadelphia | **DAVID PORTER****TRACK 2** **Clinical & Business Operations**Moderator:[Robert (Robb) E. Richards, MS, MBA](https://www.linkedin.com/in/robert-richards-7ab69917a)University of Pennsylvania | **TRISH HANKINS / PATRICIA MANAGAN****TRACK 3****Nursing Track**Moderators: [Patricia Mangan, MSN, CRNP](https://www.pennmedicine.org/providers/profile/patricia-mangan) Penn Medicine | Symposium Co-Chair[Diane Baniewicz, RN, MSN, CRNP](https://www.chop.edu/clinical-staff/baniewicz-diane)Children's Hospital of Philadelphia  | **CARL JUNE****TRACK 4****Hot Topics in Cell Therapies**Moderator:[Elizabeth O. Hexner, MD, MSTR](https://www.pennmedicine.org/providers/profile/elizabeth-hexner)Penn Medicine | **BRUCE LEVINE****TRACK 5****Commercial Partnering & Creating Products for Patients** Moderator:[John S. Swartley, MBA, PhD](https://pci.upenn.edu/team/john-s-swartley-mba-ph-d/)University of Pennsylvania |
| **Immune Mediated Bone Marrow Failure**[Timothy S. Olson, MD, PhD](https://www.chop.edu/doctors/olson-timothy-s) Children's Hospital of Philadelphia **Proteomic Analysis of CRS**[Caroline Diorio, MD, FRCPC, FAAP](https://www.chop.edu/doctors/diorio-caroline)Children's Hospital of Philadelphia**Novel Approaches for Eradication of AAV Neutralizing Antibodies**[Bhavya S. Doshi, MD](https://www.chop.edu/doctors/doshi-bhavya-s)Children's Hospital of Philadelphia**Discussion** | **Description*** *Gain a better understanding of clinical, operational, and business challenges onboarding cell and gene therapies*
* *Considerations for starting/maintaining a cell and gene therapy program*
* *Recommendations for developing cell and gene therapy programs from both the academic and community hospital perspective*

**LEGAL****Know Your Cell and Gene Therapy Contracts** **“Complexities in Agreement Terms” (CART)**[Denene M. Wambach, Esq.](https://ogc.upenn.edu/people/denene-wambach)University of Pennsylvania[Joline A. Miceli-Mullen, Esq.](https://www.linkedin.com/in/joline-miceli-mullen-8363a548)Children's Hospital of Philadelphia**Discussion****BUSINESS DEVELOPMENT****Best practices (so far) of Developing Cell and Gene Therapy Programs****Onboarding and Centralizing New Cell and Gene Therapy Products**[Mark Duckworth](https://www.chop.edu/administrative-staff/duckworth-mark-j)Children's Hospital of Philadelphia[Jennifer Harding, MPA](https://www.chop.edu/administrative-staff/harding-jennifer)Children’s Hospital of Philadelphia*(continued)***Expansion into Community**[Kaitlyn Lyons](https://www.linkedin.com/in/kaitlyn-lyons-375a7aa3/)Penn Medicine**Lancaster General Health Experience with CAR T**[Nik Buescher](https://www.linkedin.com/in/nik-buescher-91995956)Penn Medicine**Discussion** | **Description*** *Review the mechanism of action and nursing management of newly approved agents and those currently in clinical trials for hematology malignancies including bispecific antibodies*
* *Update on CAR T therapies with a focus on coordination of care of these patients*
* *Discuss the issues of fertility in our transplant and immunotherapy patients*
* *Discuss new approaches to the management of graft vs host disease*

**SPECIAL WELCOME**[Lindsey Zinck, MSN, RN, OCN, NEA-BC](https://pc3i.upenn.edu/people/lindsey-zinck/)Penn Medicine[Wendy Hobbie, RN, MSN, CRNP, FAAN](https://www.chop.edu/clinical-staff/hobbie-wendy)Children's Hospital of Philadelphia**KEYNOTES****Making Better CARTs: The progress continues**[Jakub Svoboda, MD](https://www.pennmedicine.org/providers/profile/jakub-svoboda)Penn Medicine**Fertility Preservation**[Alison W. Loren MD, MS](https://www.pennmedicine.org/providers/profile/alison-loren)Penn Medicine[Jill P. Ginsberg, MD](https://www.chop.edu/doctors/ginsberg-jill-p)Children's Hospital of Philadelphia**Discussion** | **Cell Therapies of the Present****Toxicity and Toxicity Management****(CRS/Prophylactic and Neurotoxicity)**[Noelle V. Frey, MD, MSCE](https://www.pennmedicine.org/providers/profile/noelle-frey)Penn Medicine **CAR T for Multiple Myeloma**[Edward A. Stadtmauer, MD](https://www.pennmedicine.org/providers/profile/edward-stadtmauer)Penn Medicine **CAR T Cells in CLL. Why or Why Not?**[David L. Porter, MD](https://www.pennmedicine.org/providers/profile/david-porter)Penn Medicine | Symposium Co-Chair **Mechanisms of Resistance?** **Overcoming Resistance?**[David B. Miklos, MD, PhD](https://profiles.stanford.edu/david-miklos)Stanford University **Discussion****Center for Cellular Immunotherapies** 5 minute presentations from the Muriel Joan Drew Hege Fund awardees | **$tuff You Should Know about Starting Up and Spinning Out a Cell and Gene Biotech****Panel Discussion**[Haig Aghajanian, PhD](https://www.linkedin.com/in/haig-aghajanian-4157b14/)Capstan Therapeutics[Benjamin Dibling, PhD](https://pci.upenn.edu/team/benjamin-dibling-ph-d/)University of Pennsylvania[Lauren Murdza, Esq.](https://www.dlapiper.com/en-us/people/m/lauren-murdza)DLA Piper**Academia Industry / Silicon Valley****Development of biotechnology here in Philadelphia**[John Grady](https://www.linkedin.com/in/johnsgrady/)Cancer Center Innovation Advisory Board |

**1:30 – 2:40 pm**

**CONCURRENT SESSIONS II**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **STEVE GRUPP / ALEXIS THOMAS****TRACK 1****Pediatric Nursing Care** Moderators:[Anne Wohlschlaeger, MSN, RN CRNP](https://www.chop.edu/clinical-staff/wohlschlaeger-anne)Children’s Hospital of Philadelphia[Houston Roberson, BA](https://www.chop.edu/clinical-staff/robersonc-houston)Children’s Hospital of PhiladelphiaCNE-accredited | **DAVID PORTER / TRISH HANKINS****TRACK 2****Clinical & Business Operations**Moderator: [John Simpkins, MBA](http://www.chop.edu/cccr/administrative-staff/simpkins-john)Children's Hospital of Philadelphia | **TRISH HANKINS / PATRICIA MANAGAN****TRACK 3** **Nursing Keynotes**Moderator: [Patricia Mangan, MSN, CRNP](https://www.pennmedicine.org/providers/profile/patricia-mangan) Penn Medicine | Symposium Co-Chair | **CARL JUNE****TRACK 4****Hot Topics in Cell Therapies**Moderator: [Saar I. Gill, MD, PhD](https://www.pennmedicine.org/providers/profile/saar-gill)Penn Medicine  | **BRUCE LEVINE****TRACK 5****Commercial Partnering & Creating Products for Patients** Moderator:[Asthika Goonewardene, MBA](https://www.linkedin.com/in/asthika/)Truist Securities |
| **Description*** *Considerations and challenges for pediatric patients with malignancies seeking CAR-T based therapies and patients with hemoglobinopathies seeking BMT or cellular based gene therapies*
* *Exciting pediatric case reviews of Viral CTL’s, NBL CART and CD19/22 CART*
* *An innovative, collaborative approach to the stem cell day infusion procedure*

*All speakers from Children’s Hospital of Philadelphia***Navigation and Coordination of These Complex Therapeutics****Considerations & Challenges for Patients with Malignancies Seeking CAR-T Based Therapies**[Brooke Leibfreid, BSN, RN](https://www.chop.edu/clinical-staff/leibfreid-brooke) **Considerations & Challenges for Patients with Hemoglobinopathies Seeking BMT or Cellular Based Gene Therapies** [Denise Belcher, MBA](https://www.linkedin.com/in/denise-belcher)[Kelly E. Heffner, MSW](https://www.chop.edu/clinical-staff/heffner-kelly)[Elizabeth A. Worster MSN, CRNP](https://www.chop.edu/nurse-practitioners/worster-elizabeth-a)**Case Reviews**Viral CTLs[Barbara McGlynn, BSN, RN](https://www.chop.edu/clinical-staff/mcglynn-barbara)[Samantha Barone, MSN, CPNP-AC, CPHON](https://www.chop.edu/nurse-practitioners/barone-samantha)*(continued)*NBL CART[Diane Baniewicz, RN, MSN, CRNP](https://www.chop.edu/clinical-staff/baniewicz-diane)CD19/22 CART[Colleen Callahan, RN, MSN, CRNP](https://www.chop.edu/clinical-staff/callahan-colleen)**Infusing Collaboration: Stem Cell Infusion Day Procedures**[Anna D’Aprile, MSN, RN, CPHON](https://www.linkedin.com/in/anna-d%E2%80%99aprile-635b715a/)[Eleni Hindle, CPHON](https://www.linkedin.com/in/eleni-hindle-36b6063b/)**Discussion** | **Description***As the number of Cell and Gene Therapies rapidly emerge, hospital administrators and business teams continue to look for strategies and solutions to navigate this ever-changing treatment landscape. This session will discuss the challenges and best practices to:** *Onboard new cell and gene therapies*
* *How to deliver these products efficiently and safely*
* *Best practices and strategies for scaling your cell and gene therapy program*

**EDUCATION****How do you Organize/Develop Onboarding of Staff/Sites as Cell and Gene Therapy Expands?****Onboarding Staff and new Divisions as Cell and Gene Therapy Expands (Site Perspective)**[Beth McBride](https://www.chop.edu/clinical-staff/mcbride-elizabeth-a)Children's Hospital of Philadelphia**Developing Tools to Widen Patient Access to Complex Therapies (Health System)**[Robert (Robb) E. Richards, MS, MBA](https://www.linkedin.com/in/robert-richards-7ab69917a)University of Pennsylvania**Discussion***(continued)***OPERATIONS****The Challenges of Operationalizing Cell and Gene Therapies****Strategies and Challenges facing Apheresis and Cell and Gene Therapy Labs**[René Machietto, MS, MLS (ASCP)CM](https://www.chop.edu/administrative-staff/machietto-ren) Children's Hospital of PhiladelphiaMandy Shanahan, MSN, RN, LSSGB, CPHQChildren’s Hospital of Philadelphia**Expanding Access to Cell Therapies: Integrating Advanced Treatments into Community Healthcare Settings****Mismatched Transplants**[Steven Devine, MD](https://www.vorbio.com/team/steven-devine/)Center for International Blood and Marrow Transplant Research**CAR T Cells in the community** (include Lancaster General Update)[Kaitlyn Lyons](https://www.linkedin.com/in/kaitlyn-lyons-375a7aa3/)Penn Medicine[David Porter, MD](https://www.pennmedicine.org/providers/profile/david-porter)Penn Medicine**Panel Discussion**[David Porter, MD](https://www.pennmedicine.org/providers/profile/david-porter)Penn Medicine[Steven Devine, MD](https://www.vorbio.com/team/steven-devine/)Center for International Blood and Marrow Transplant Research[Carrie Marvill](https://www.linkedin.com/in/carrie-marvill-90902a168/)Penn Medicine[Kaitlyn Lyons](https://www.linkedin.com/in/kaitlyn-lyons-375a7aa3/)Penn Medicine[Madelyn Fell, MHA](https://www.linkedin.com/in/madelyn-fell-7407b0113/)[Nicole Kanuck BSN, RN](https://www.linkedin.com/in/nicole-kanuck-walls-bsn-rn-1532605)NMDP[Tim Beer](https://www.linkedin.com/in/tim-beer-403397156)Penn Medicine Lancaster General Health **Additional topics**– Insurance Horror Stories/ Insurance Approvals – [Skysona ALS (gene therapy)](https://www.skysona.com/) – [Pz-cel Treatment for New and Previously Treated Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)](https://www.abeonatherapeutics.com/clinical-trials/rdeb)[– Enzyvant Receives FDA Approval for RETHYMIC*®* (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia](https://www.us.sumitomo-pharma.com/newsroom/press-releases/Enzyvant-Receives-FDA-Approval-for-RETHYMIC-allogeneic-processed-thymus-tissue-agdc-a-One-Time-Regenerative-Tissue-Based-Therapy-for-Pediatric/) | *All speakers from Penn Medicine***Bispecifics** [Patricia Mangan, MSN, CRNP](https://www.pennmedicine.org/providers/profile/patricia-mangan)**Research in Real Time**[Rachel Lundberg, PA-C](https://www.pennmedicine.org/providers/profile/rachel-lundberg)**Case Reviews**Chronic Graft Versus Host Disease[Linda M. Perry, PA-C](https://www.pennmedicine.org/providers/profile/linda-perry)Lymphoma Bispecific Antibody Therapy and Management of CRS[Danielle Land, MSN, CRNP](https://www.pennmedicine.org/providers/profile/danielle-land) [Mitchell E. Hughes, PharmD, BCOP](https://www.linkedin.com/in/mitchell-e-hughes-264a6894/)Navigating the Complexities of CAR-T Care[Elizabeth A. Weber, RN, BSN](https://www.linkedin.com/in/lizzie-weber-21411574)**Discussion** | **Cell Therapies of the Future****Mesenchymal Stem Cells and Their Exosomes for Gene Delivery**[Elizabeth J. Shpall, MD](https://faculty.mdanderson.org/profiles/elizabeth_shpall.html)MD Anderson Cancer Center **More Than Just T Cells: CAR macrophage or gene engineering of stem cells to generate CAR T resistance**[Saar I. Gill, MD, PhD](https://www.pennmedicine.org/providers/profile/saar-gill)Penn Medicine **Chimeric Antigen Receptor T Cells for T Cell Malignancies**[Marco Ruella, MD](https://www.pennmedicine.org/providers/profile/marco-ruella)Penn Medicine **Imaging Cellular Therapies with PET Imaging**[Michael D. Farwell, MD](https://www.pennmedicine.org/providers/profile/michael-farwell?fadf=pennmedicine&_ga=2.6620530.1922048999.1646405487-386578529.1639084756)Penn Medicine**Discussion** | **$tuff You Should Know about Financing a Cell and Gene Therapy Startup****Panel Discussion**[Michael Allwin](https://www.linkedin.com/in/michael-allwin-777814ab/)Truist Securities[Christiana Bardon, MD, MBA](https://www.linkedin.com/in/christiana-bardon-m-d-2461bb/)BioImpact Capital[Carter Caldwell, MBA](https://www.linkedin.com/in/carter-caldwell-07b13810/)Penn Medicine |

**2:45 – 3:40 pm**

**CONCURRENT SESSIONS III**

|  |  |
| --- | --- |
| **TRACK 1****Covering the Cost of Cell Therapy: Financing and Advocacy**Moderator: [David L. Porter, MD](https://www.pennmedicine.org/providers/profile/david-porter) | Penn Medicine | Symposium Co-Chair  | **(TBD)****Hot Topics in CAR’s***This session features leading experts presenting cutting-edge research on innovative approaches in the field of CAR-T therapy. Donald M. O'Rourke, MD, will discuss the promising application of bivalent CARs in treating Glioblastoma, highlighting their potential to enhance efficacy by targeting multiple antigens simultaneously. Neil C. Sheppard D.Phil will explore the exciting combination of CAR-T therapy with oncolytic viruses in solid tumors, demonstrating the synergistic effect of these therapies in improving tumor recognition and immune response. Additionally, Mike C. Milone, MD, PhD, will delve into the development of autoimmune targeted CARs, presenting strategies to engineer CAR-T cells that selectively target and treat autoimmune diseases, offering a new paradigm for precision immunotherapy.*Moderator: [Bruce L. Levine, PhD](http://pathology.med.upenn.edu/department/people/291/bruce-l-levine) | Penn Medicine | Symposium Co-Chair |
|  **2:45 pm TBA**[Kevin B. Mahoney, DBA](https://ldi.upenn.edu/expert/kevin-b-mahoney) | Penn Medicine  **3:00 pm Provider Solutions - Where We Are and Where We Should Be?**[Mark Trusheim, MS](https://www.linkedin.com/in/mark-trusheim-6ab1542) | NEWDIGS [Claire M. White, MSN, RN](https://www.chop.edu/clinical-staff/white-claire)  |  Children's Hospital of Philadelphia  **3:15 pm Striving for Equitable Access – Challenges and Opportunities**[Louis J. DeGennaro, PhD](https://www.lls.org/person/louis-j-degennaro-phd) | Leukemia & Lymphoma Society  **3:30 pm Discussion** |  **2:45 pm Bivalent CAR’s in Glioblastoma**[Donald M. O'Rourke, MD](https://www.pennmedicine.org/providers/profile/donald-orourke) | Penn Medicine  **3:00 pm Combination of CAR-T and Oncolytic Virus in Solid Tumors**[Neil C. Sheppard, DPhil](https://www.med.upenn.edu/cci/sheppardlab/) | Penn Medicine  **3:15 pm Autoimmune Targeted CAR’s**[Mike C. Milone, MD, PhD](https://pathology.med.upenn.edu/department/people/439/michael-c-milone) | Penn Medicine **3:30 pm Discussion****2:45 pm TBD**[Donald M. O'Rourke, MD](https://www.pennmedicine.org/providers/profile/donald-orourke) | Penn Medicine  **3:00 pm TBD** **3:15 pm TBD**  **3:30 pm Discussion** |